Repositioning rifamycins for Mycobacterium abscessus lung disease

References

• Tortoli E. Chapter 1 - The Taxonomy of the Genus Mycobacterium. In: Velayati AA, Farnia P, editors. Nontuberculous Mycobacteria (NTM). Cambridge (MA): Academic Press; 2019. p. 1–10.
   Google Scholar
• Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015 Apr;36(2):217–224. . PubMed PMID: 25826589
   PubMed Web of Science ®Google Scholar
• Daniel-Wayman S, Adjemian J, Rebecca Prevots D. Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) in the USA. In: Griffith DE, editor. Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management. Cham: Springer International Publishing; 2019. p. 145–161.
   Google Scholar
• Wassilew N, Hoffmann H, Andrejak C, et al. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration. 2016;91(5):386–402. . PubMed PMID: 27207809
   PubMed Web of Science ®Google Scholar
• Strollo SE, Adjemian J, Adjemian MK, et al. The Burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc. 2015 Oct;12(10):1458–1464. PubMed PMID: 26214350; PubMed Central PMCID: PMCPMC4627421.
   PubMed Web of Science ®Google Scholar
• Adjemian J, Frankland TB, Daida YG, et al. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017 Mar;23(3):439–447. PubMed PMID: 28221128; PubMed Central PMCID: PMCPMC5382761.
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Vu A, Leitman P, et al. A patient-based analysis of the geographic distribution of mycobacterium avium complex, mycobacterium abscessus, and mycobacterium kansasii infections in the United States. Chest. 2017 Apr;151(4):947–950. PubMed PMID: 28390637.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Longworth S, Mezochow A, et al. Deaths related to nontuberculous mycobacterial infections in the United States, 1999-2014. Ann Am Thorac Soc. 2016 Nov;13(11):1951–1955. PubMed PMID: 27607541; PubMed Central PMCID: PMCPMC5122483.
   PubMed Web of Science ®Google Scholar
• Maurer FP, Bruderer VL, Ritter C, et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother. 2014 Jul;58(7):3828–3836. PubMed PMID: 24752273; PubMed Central PMCID: PMCPMC4068550.
   PubMed Web of Science ®Google Scholar
• Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in mycobacterium abscessus drug resistance. Front Microbiol. 2018;9:2179. PubMed PMID: 30258428; PubMed Central PMCID: PMCPMC6143652.
   PubMed Web of Science ®Google Scholar
• Falkinham JO 3rd. Challenges of NTM Drug Development. Front Microbiol. 2018;9:1613. . PubMed PMID: 30072975; PubMed Central PMCID: PMCPMC6058048
   PubMed Web of Science ®Google Scholar
• Philley JV, Griffith DE. Disease Caused by Mycobacterium Abscessus and Other Rapidly Growing Mycobacteria (RGM). In: Griffith DE, editor. Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management. Cham: Springer International Publishing; 2019. p. 369–399.
   Google Scholar
• Dal Molin M, Gut M, Rominski A, et al. Molecular mechanisms of intrinsic streptomycin resistance in mycobacterium abscessus. Antimicrob Agents Chemother. 2018 Jan;62(1). PubMed PMID: 29061744; PubMed Central PMCID: PMCPMC5740355. DOI:10.1128/AAC.01427-17.
   PubMed Web of Science ®Google Scholar
• Rominski A, Roditscheff A, Selchow P, et al. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother. 2017 Feb;72(2):376–384. . PubMed PMID: 27999011.
   PubMed Web of Science ®Google Scholar
• Rominski A, Schulthess B, Muller DM, et al. Effect of beta-lactamase production and beta-lactam instability on MIC testing results for Mycobacterium abscessus. J Antimicrob Chemother. 2017 Nov 1;72(11):3070–3078. PubMed PMID: 28961987.
   PubMed Web of Science ®Google Scholar
• Rominski A, Selchow P, Becker K, et al. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. J Antimicrob Chemother. 2017 May 09. DOI:10.1093/jac/dkx125. [ PubMed PMID: 28486671].
   Web of Science ®Google Scholar
• Rudra P, Hurst-Hess K, Lappierre P, et al. High levels of intrinsic tetracycline resistance in mycobacterium abscessus are conferred by a tetracycline-modifying monooxygenase. Antimicrob Agents Chemother. 2018 Jun;62(6). PubMed PMID: 29632012; PubMed Central PMCID: PMCPMC5971581. DOI:10.1128/AAC.00119-18.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. PubMed PMID: 17277290.
   PubMed Web of Science ®Google Scholar
• Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009 Apr;53(4):1367–1376. . PubMed PMID: 19171799; PubMed Central PMCID: PMCPMC2663066
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Benwill JL, et al. Mycobacterium abscessus. “Pleased to meet you, hope you guess my name”. Ann Am Thorac Soc. 2015 Mar;12(3):436–439. PubMed PMID: 25643064.
   PubMed Web of Science ®Google Scholar
• Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011 Mar 1;52(5):565–571. PubMed PMID: 21292659.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009 Jun;64(6):502–506. PubMed PMID: 19213773.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011 Feb 1;183(3):405–410. PubMed PMID: 20833823.
   PubMed Web of Science ®Google Scholar
• Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015 Mar;36(1):67–78. . PubMed PMID: 25676520
   PubMed Web of Science ®Google Scholar
• Andrejak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010 Mar 1;181(5):514–521. PubMed PMID: 20007929.
   PubMed Web of Science ®Google Scholar
• Jenkins PA, Campbell IA. Research committee of the british thoracic s. pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med. 2003 Apr;97(4):439–444. PubMed PMID: 12693807
   PubMed Web of Science ®Google Scholar
• Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018 Apr 7. PubMed PMID: 29635026. DOI:10.1016/j.drudis.2018.04.001
   Web of Science ®Google Scholar
• ClinicalTrials.gov: U.S. national library of medicine; [cited 2019 April 24]. Available from: https://clinicaltrials.gov
   Google Scholar
• Daley CL, Olivier KN. ALIS (Amikacin Liposome Inhalation Suspension): the Beginning of a Wonderland? Am J Respir Crit Care Med. 2018 Oct 26. DOI:10.1164/rccm.201810-1901ED. PubMed PMID: 30365392.
   Web of Science ®Google Scholar
• Griffith DE, Eagle G, Thomson R, et al. amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018 Sep 14. DOI:10.1164/rccm.201807-1318OC. [ PubMed PMID: 30216086].
   Web of Science ®Google Scholar
• Daniel-Wayman S, Abate G, Barber DL, et al. Advancing translational science for pulmonary nontuberculous mycobacterial infections. a road map for research. Am J Respir Crit Care Med. 2019 Apr 15;199(8):947–951. PubMed PMID: 30428263.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG, Hansen RA. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Pethe K, Sequeira PC, Agarwalla S, et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun. 2010;1:57. . PubMed PMID: 20975714; PubMed Central PMCID: PMC3220188
   PubMed Web of Science ®Google Scholar
• Sarathy JP, Via LE, Weiner D, et al. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. 2018 Feb;62(2). PubMed PMID: 29203492; PubMed Central PMCID: PMCPMC5786764. DOI:10.1128/AAC.02266-17.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012 Apr;25(2):218–227. . PubMed PMID: 22327466
   PubMed Web of Science ®Google Scholar
• An antibiotic comeback? Nat Rev Drug Discov. 2014 02/28/online; 13:165. .
   Web of Science ®Google Scholar
• Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;Jul-Aug;5(Suppl 3):S402–6. PubMed PMID: 6635432.
   Google Scholar
• Maggi N, Pasqualucci CR, Ballotta R, et al. Rifampicin: a new orally active rifamycin. Chemotherapy. 1966;11(5):285–292. PubMed PMID: 5958716.
   PubMed Web of Science ®Google Scholar
• Calvori C, Frontali L, Leoni L, et al. Effect of rifamycin on protein synthesis. Nature. 1965 Jul 24;207(995):417–418. PubMed PMID: 4957347
   PubMedGoogle Scholar
• Hartmann G, Honikel KO, Knusel F, et al. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145(3):843–844. PubMed PMID: 4863911
   PubMedGoogle Scholar
• Yarbrough LR, Wu FY, Wu CW. Molecular mechanism of the rifampicin -RNA polymerase interaction. Biochemistry. 1976 Jun 15;15(12):2669–2676. PubMed PMID: 779828
   PubMed Web of Science ®Google Scholar
• Arioli V, Pallanza R, Furesz S, et al. Rifampicin: a new rifamycin. I. Bacteriological studies. Arzneimittelforschung. 1967 May;17(5):523–529. PubMed PMID: 4385644
   PubMedGoogle Scholar
• Pallanza R, Arioli V, Furesz S, et al. Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations. Arzneimittelforschung. 1967 May;17(5):529–534. PubMed PMID: 5631580
   PubMedGoogle Scholar
• Lancini G, Pallanza R, Silvestri LG. Relationships between bactericidal effect and inhibition of ribonucleic acid nucleotidyltransferase by rifampicin in Escherichia coli K-12. J Bacteriol. 1969 Feb;97(2):761–768. PubMed PMID: 4886292; PubMed Central PMCID: PMCPMC249757
   PubMed Web of Science ®Google Scholar
• Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev. 1981;12(1):159–218. . PubMed PMID: 7028436
   PubMed Web of Science ®Google Scholar
• Lakshminarayana SB, Huat TB, Ho PC, et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother. 2015 Mar;70(3):857–867. PubMed PMID: 25587994.
   PubMed Web of Science ®Google Scholar
• Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015 Oct;21(10):1223–1227. PubMed PMID: 26343800; PubMed Central PMCID: PMCPMC4598290.
   PubMed Web of Science ®Google Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231–79. PubMed PMID: 10529902
   PubMed Web of Science ®Google Scholar
• Chopra S, Matsuyama K, Hutson C, et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother. 2011 Jul;66(7):1533–1536. PubMed PMID: 21486854.
   PubMed Web of Science ®Google Scholar
• Pang H, Li G, Zhao X, et al. Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China. Biomed Res Int. 2015;2015:419392. . PubMed PMID: 26351633; PubMed Central PMCID: PMCPMC4550772
   PubMedGoogle Scholar
• Sha W, Weng XH, Xiao HP, et al. [Investigation of drug-resistance to rifampin and rpoB gene sequence analysis of Mycobacterium abscessus]. Zhonghua Jie He He Hu Xi Za Zhi. 2003 Sep;26(9):544–547. PubMed PMID: 14521758
   PubMedGoogle Scholar
• Lambert PA. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J Appl Microbiol. 2002;92(Suppl):46S–54S. PubMed PMID: 12000612
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29–63. PubMed PMID: 7574484.
   PubMed Web of Science ®Google Scholar
• Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett. 1994 Oct 15;123(1–2):11–18. . PubMed PMID: 7988876.
   PubMed Web of Science ®Google Scholar
• Hohl M, Remm S, Eskandarian HA, et al. Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG. Mol Microbiol. 2019 Feb 11. DOI:10.1111/mmi.14220. [ PubMed PMID: 30742339].
   PubMed Web of Science ®Google Scholar
• Becker K, Haldimann K, Selchow P, et al. Lipoprotein glycosylation by protein-o-mannosyltransferase (MAB_1122c) contributes to low cell envelope permeability and antibiotic resistance of mycobacterium abscessus. Front Microbiol. 2017;8:2123. . PubMed PMID: 29163413; PubMed Central PMCID: PMCPMC5673659
   PubMed Web of Science ®Google Scholar
• Ripoll F, Pasek S, Schenowitz C, et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One. 2009 Jun 19;4(6):e5660. PubMed PMID: 19543527; PubMed Central PMCID: PMCPMC2694998.
   PubMed Web of Science ®Google Scholar
• Balganesh M, Dinesh N, Sharma S, et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother. 2012 May;56(5):2643–2651. PubMed PMID: 22314527; PubMed Central PMCID: PMCPMC3346595.
   PubMed Web of Science ®Google Scholar
• Szumowski JD, Adams KN, Edelstein PH, et al. Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol. 2013;374:81–108. . PubMed PMID: 23242857; PubMed Central PMCID: PMCPMC3859842
   PubMed Web of Science ®Google Scholar
• Baysarowich J, Koteva K, Hughes DW, et al. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4886–4891. PubMed PMID: 18349144; PubMed Central PMCID: PMCPMC2290778.
   PubMed Web of Science ®Google Scholar
• Koteva K, Cox G, Kelso JK, et al. Rox, a rifamycin resistance enzyme with an unprecedented mechanism of action. Cell Chem Biol. 2018 Apr 19;25(4):403–412 e5. PubMed PMID: 29398560.
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012 Jun;15(3):149–161. PubMed PMID: 22525524.
   PubMed Web of Science ®Google Scholar
• Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus Complex. Semin Respir Crit Care Med. 2018 Jun;39(3):362–376. . PubMed PMID: 30071551
   PubMed Web of Science ®Google Scholar
• Aziz DB, Low JL, Wu ML, et al. Rifabutin is active against mycobacterium abscessus complex. Antimicrob Agents Chemother. 2017 Apr 10. PubMed PMID: 28396540. DOI:10.1128/AAC.00155-17
   PubMed Web of Science ®Google Scholar
• Le Run E, Arthur M, Mainardi JL. In vitro and intracellular activity of imipenem combined with rifabutin and avibactam against mycobacterium abscessus. Antimicrob Agents Chemother. 2018 Aug;62(8). DOI:10.1128/AAC.00623-18. PubMed PMID: 29866869; PubMed Central PMCID: PMCPMC6105861.
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn S, Hwang NY, et al. Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis. Int J Infect Dis. 2017 Dec;65:135–141. PubMed PMID: 29224631.
   PubMed Web of Science ®Google Scholar
• Griffith DE. Treatment of Mycobacterium avium Complex (MAC). Semin Respir Crit Care Med. 2018 Jun;39(3):351–361. . PubMed PMID: 30071550
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996 Apr;22(Suppl 1):S15-21; discussion S21-2. PubMed PMID: 8785251
   PubMedGoogle Scholar
• Van der Auwera P, Matsumoto T, Husson M. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother. 1988 Aug;22(2):185–192. PubMed PMID: 2846489
   PubMed Web of Science ®Google Scholar
• Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 2):S1–25. PubMed PMID: 9279284.
   PubMed Web of Science ®Google Scholar
• Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact. 1997 Nov 6;107(1–2):17–30. PubMed PMID: 9402947
   PubMed Web of Science ®Google Scholar
• Reinach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact. 1999 Jun 1;121(1):37–48. PubMed PMID: 10418969
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013 Jan;29(1):1–12. PubMed PMID: 23136913.
   PubMed Web of Science ®Google Scholar
• Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011 Nov;15(11):1485–9, i. . PubMed PMID: 22008761; PubMed Central PMCID: PMCPMC3290133
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents. 2010 Feb;35(2):169–173. PubMed PMID: 20006470.
   PubMed Web of Science ®Google Scholar
• Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis. 1996 Apr;22(Suppl 1):S3-13; discussion S13-4. PubMed PMID: 8785253
   PubMedGoogle Scholar
• Buss WC, Reyes E, Barela TD Metal ion catalyzed oxidation of the antibiotic rifampicin. Res Commun Chem Pathol Pharmacol. 1977 Jul;17(3):547–550. PubMed PMID: 19824.
   PubMedGoogle Scholar
• Staudinger T, Redl B, Glasgow BJ. Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin. Biochim Biophys Acta. 2014 Apr;1844(4):750–758. . PubMed PMID: 24530503; PubMed Central PMCID: PMCPMC3992280
   PubMed Web of Science ®Google Scholar
• Spanogiannopoulos P, Waglechner N, Koteva K, et al. A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria. Proc Natl Acad Sci U S A. 2014 May 13;111(19):7102–7107. PubMed PMID: 24778229; PubMed Central PMCID: PMCPMC4024899.
   PubMed Web of Science ®Google Scholar
• Spanogiannopoulos P, Thaker M, Koteva K, et al. Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes. Antimicrob Agents Chemother. 2012 Oct;56(10):5061–5069. PubMed PMID: 22802246; PubMed Central PMCID: PMCPMC3457401.
   PubMed Web of Science ®Google Scholar
• Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature. 2017 May 18;545(7654):299–304. PubMed PMID: 28489819; PubMed Central PMCID: PMCPMC5737020.
   PubMed Web of Science ®Google Scholar
• Pryjma M, Burian J, Thompson CJ. Rifabutin acts in synergy and is bactericidal with frontline mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination. Antimicrob Agents Chemother. 2018 Aug;62(8). DOI:10.1128/AAC.00283-18. PubMed PMID: 29760147; PubMed Central PMCID: PMCPMC6105836.
   PubMed Web of Science ®Google Scholar
• Cheng A, Tsai YT, Chang SY, et al. In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019 Apr;63(4). DOI:10.1128/AAC.02234-18. PubMed PMID: 30670428.
   Web of Science ®Google Scholar
• Pryjma M, Burian J, Kuchinski K, et al. Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of mycobacterium abscessus infections is mediated by the whiB7 gene. Antimicrob Agents Chemother. 2017 Nov;61(11). PubMed PMID: 28874379; PubMed Central PMCID: PMCPMC5655113. DOI:10.1128/AAC.01353-17.
   PubMed Web of Science ®Google Scholar
• Soroka D, Dubee V, Soulier-Escrihuela O, et al. Characterization of broad-spectrum Mycobacterium abscessus class A beta-lactamase. J Antimicrob Chemother. 2014 Mar;69(3):691–696. PubMed PMID: 24132992.
   PubMed Web of Science ®Google Scholar
• Lavollay M, Dubee V, Heym B, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2014 May;20(5):O297–300. PubMed PMID: 24112243.
   PubMed Web of Science ®Google Scholar
• Story-Roller E, Maggioncalda EC, Lamichhane G. Select beta-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro. Antimicrob Agents Chemother. 2019 Feb 11. DOI:10.1128/AAC.02613-18. PubMed PMID: 30745389.
   Web of Science ®Google Scholar
• Ferro BE, Srivastava S, Deshpande D, et al. Tigecycline is highly efficacious against mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother. 2016 May;60(5):2895–2900. PubMed PMID: 26926649; PubMed Central PMCID: PMCPMC4862465.
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014 Jul;69(7):1945–1953. PubMed PMID: 24633206; PubMed Central PMCID: PMCPMC4054987.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria. J Clin Microbiol. 2017 Jun;55(6):1747–1754. . PubMed PMID: 28330892; PubMed Central PMCID: PMCPMC5442531
   PubMed Web of Science ®Google Scholar
• Kim TS, Choe JH, Kim YJ, et al. Activity of LCB01-0371, a novel oxazolidinone, against mycobacterium abscessus. Antimicrob Agents Chemother. 2017 Sep;61(9). PubMed PMID: 28674049; PubMed Central PMCID: PMCPMC5571369. DOI:10.1128/AAC.02752-16.
   Web of Science ®Google Scholar
• Le Run E, Arthur M, Mainardi JL. In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against mycobacterium abscessus. Antimicrob Agents Chemother. 2019 Apr;63(4). DOI:10.1128/AAC.01915-18. PubMed PMID: 30745387.
   PubMed Web of Science ®Google Scholar
• Hawn TR, Matheson AI, Maley SN, et al. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev. 2013 Dec;77(4):608–627. PubMed PMID: 24296574; PubMed Central PMCID: PMCPMC3973381.
   PubMed Web of Science ®Google Scholar
• Kolloli A, Subbian S. Host-directed therapeutic strategies for tuberculosis. Front Med (Lausanne). 2017;4:171. . PubMed PMID: 29094039; PubMed Central PMCID: PMCPMC5651239
   PubMed Web of Science ®Google Scholar
• Burton EA, Plattner R, Pendergast AM. Abl tyrosine kinases are required for infection by Shigella flexneri. Embo J. 2003 Oct 15;22(20):5471–5479. . PubMed PMID: 14532119; PubMed Central PMCID: PMCPMC213767.
   PubMed Web of Science ®Google Scholar
• Elwell CA, Ceesay A, Kim JH, et al. RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog. 2008 Mar 7;4(3):e1000021. PubMed PMID: 18369471; PubMed Central PMCID: PMCPMC2267011.
   PubMed Web of Science ®Google Scholar
• Pielage JF, Powell KR, Kalman D, et al. RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization. PLoS Pathog. 2008 Mar 21;4(3):e1000031. PubMed PMID: 18369477; PubMed Central PMCID: PMCPMC2265438.
   PubMed Web of Science ®Google Scholar
• Napier RJ, Rafi W, Cheruvu M, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe. 2011 Nov 17;10(5):475–485. PubMed PMID: 22100163; PubMed Central PMCID: PMCPMC3222875.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005 Jan 7;307(5706):58–62. . PubMed PMID: 15637262.
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014 Nov 10;26(5):605–622. . PubMed PMID: 25517747; PubMed Central PMCID: PMCPMC4269830.
   PubMed Web of Science ®Google Scholar
• Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014 Mar;12(3):159–167. . PubMed PMID: 24487820; PubMed Central PMCID: PMC4341982
   PubMed Web of Science ®Google Scholar
• Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1827–1832. PubMed PMID: 25624495; PubMed Central PMCID: PMCPMC4330784.
   PubMed Web of Science ®Google Scholar
• Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature. 2015 Jan 29;517(7536):612–615. PubMed PMID: 25470057; PubMed Central PMCID: PMCPMC4312197.
   PubMed Web of Science ®Google Scholar
• Choi SW, Gu Y, Peters RS, et al. Ambroxol induces autophagy and potentiates rifampin antimycobacterial activity. Antimicrob Agents Chemother. 2018 Sep;62(9). DOI:10.1128/AAC.01019-18. PubMed PMID: 30012752; PubMed Central PMCID: PMCPMC6125555.
   Web of Science ®Google Scholar
• Imaoka M. [Preclinical and clinical investigation about combination effects of expectorants in chemotherapy of infectious respiratory diseases]. Chemotherapy. 1986;34(3):262–270.
   Google Scholar
• van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011 May;52(9):e194–9. . PubMed PMID: 21467012.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Senda C, Kishimoto W, et al. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000 Jan;30(1):71–80. PubMed PMID: 10659952
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998 Sep 1;102(5):1016–1023. PubMed PMID: 9727070; PubMed Central PMCID: PMCPMC508967.
   PubMed Web of Science ®Google Scholar
• Lee C-K, Choi J-S. Effect of clarithromycin on the pharmacokinetics of ambroxol in rats. J Pharm Invest. 2006;36(3):157–160.
   Google Scholar
• Peek J, Lilic M, Montiel D, et al. Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism. Nat Commun. 2018 Oct 8;9(1):4147. 10.1038/s41467-018-06587-2. PubMed PMID: 30297823; PubMed Central PMCID: PMCPMC6175910.
   PubMedGoogle Scholar
• Mosaei H, Molodtsov V, Kepplinger B, et al. Mode of action of kanglemycin a, an ansamycin natural product that is active against rifampicin-resistant mycobacterium tuberculosis. Mol Cell. 2018 Oct 18;72(2):263–274 e5. PubMed PMID: 30244835; PubMed Central PMCID: PMCPMC6202310.
   PubMed Web of Science ®Google Scholar
• Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001 Mar 23;104(6):901–912. PubMed PMID: 11290327
   PubMed Web of Science ®Google Scholar
• Sensi P, Maggi N, Furesz S, et al. Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother (Bethesda). 1966;6:699–714. PubMed PMID: 4862170.
   PubMedGoogle Scholar
• Combrink KD, Denton DA, Harran S, et al. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett. 2007 Jan 15;17(2):522–526. PubMed PMID: 17070048.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999 Apr;43(4):738–744. PubMed PMID: 10103174; PubMed Central PMCID: PMCPMC89200.
   PubMed Web of Science ®Google Scholar
• Collu F, Vargiu AV, Dreier J, et al. Recognition of imipenem and meropenem by the RND-transporter MexB studied by computer simulations. J Am Chem Soc. 2012 Nov 21;134(46):19146–19158. PubMed PMID: 23146101.
   PubMed Web of Science ®Google Scholar
• Dick T, Lee BH, Murugasu-Oei B. Oxygen depletion induced dormancy in Mycobacterium smegmatis. FEMS Microbiol Lett. 1998 Jun 15;163(2):159–164. PubMed PMID: 9673018
   PubMed Web of Science ®Google Scholar
• Wu ML, Gengenbacher M, Dick T. Mild nutrient starvation triggers the development of a small-cell survival morphotype in mycobacteria. Front Microbiol. 2016;7:947. . PubMed PMID: 27379076; PubMed Central PMCID: PMCPMC4909757
   PubMed Web of Science ®Google Scholar
• Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later [Research Support, Non-U.S. Gov’t Review]. Future Microbiol. 2012 Apr;7(4):513–518. . PubMed PMID: 22439727; eng
   PubMed Web of Science ®Google Scholar
• Gerasimova A, Kazakov AE, Arkin AP, et al. Comparative genomics of the dormancy regulons in mycobacteria. J Bacteriol. 2011 Jul;193(14):3446–3452. PubMed PMID: 21602344; PubMed Central PMCID: PMCPMC3133309.
   PubMed Web of Science ®Google Scholar
• Roux AL, Viljoen A, Bah A, et al. The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages. Open Biol. 2016 Nov;6(11). PubMed PMID: 27906132; PubMed Central PMCID: PMCPMC5133439. DOI:10.1098/rsob.160185.
   PubMed Web of Science ®Google Scholar
• Adams KN, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011 Apr 1;145(1):39–53. PubMed PMID: 21376383; PubMed Central PMCID: PMC3117281.
   PubMed Web of Science ®Google Scholar
• Qvist T, Eickhardt S, Kragh KN, et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J. 2015 Dec;46(6):1823–1826. 10.1183/13993003.01102-2015. PubMed PMID: 26493807
   PubMed Web of Science ®Google Scholar
• Fennelly KP, Ojano-Dirain C, Yang Q, et al. Biofilm Formation by Mycobacterium abscessus in a Lung Cavity. Am J Respir Crit Care Med. 2016 Mar 15;193(6):692–693. PubMed PMID: 26731090.
   PubMed Web of Science ®Google Scholar
• Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy? J Antimicrob Chemother. 2001 Jan;47(1):117–118. PubMed PMID: 11152444
   PubMed Web of Science ®Google Scholar
• Bernut A, Herrmann JL, Ordway D, et al. The diverse cellular and animal models to decipher the physiopathological traits of mycobacterium abscessus infection. Front Cell Infect Microbiol. 2017;7:100. PubMed PMID: 28421165; PubMed Central PMCID: PMCPMC5378707.
   PubMed Web of Science ®Google Scholar
• Lerat I, Cambau E, Roth Dit Bettoni R, et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis. 2014 Mar;209(6):905–912. PubMed PMID: 24253289.
   PubMed Web of Science ®Google Scholar
• Obregon-Henao A, Arnett KA, Henao-Tamayo M, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother. 2015 Nov;59(11):6904–6912. PubMed PMID: 26303795; PubMed Central PMCID: PMCPMC4604395.
   PubMed Web of Science ®Google Scholar
• Low JL, Wu ML, Aziz DB, et al. Screening of TB actives for activity against nontuberculous mycobacteria delivers high hit rates. Front Microbiol. 2017;8:1539. . PubMed PMID: 28861054; PubMed Central PMCID: PMCPMC5559473
   PubMed Web of Science ®Google Scholar
• Ballell L, Bates RH, Young RJ, et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. Chem Med Chem. 2013 Feb;8(2):313–321. PubMed PMID: 23307663; PubMed Central PMCID: PMCPMC3743164.
   Google Scholar
• Lin W, Mandal S, Degen D, et al. Structural basis of mycobacterium tuberculosis transcription and transcription inhibition. Mol Cell. 2017 Apr 20;66(2):169–179 e8. PubMed PMID: 28392175; PubMed Central PMCID: PMCPMC5438085.
   PubMed Web of Science ®Google Scholar
• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019 May;25(5):730–733. PubMed PMID: 31068712.
   PubMed Web of Science ®Google Scholar
• Development of antibacterial drugs for the treatment of nontuberculous mycobacterial disease: U.S. food and drug administration; [cited 2019 April 24]. Available from: https://www.fda.gov/drugs/development-antibacterial-drugs-treatment-nontuberculous-mycobacterial-disease-04082019-04082019
   Google Scholar